NCT03275480

Brief Summary

Database of Institut Paoli-Calmettes patients diagnosed with Myelodysplastic Syndromes

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
54mo left

Started Jan 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Jan 2016Dec 2030

Study Start

First participant enrolled

January 18, 2016

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

September 6, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 7, 2017

Completed
12.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

May 14, 2019

Status Verified

May 1, 2019

Enrollment Period

14 years

First QC Date

September 6, 2017

Last Update Submit

May 13, 2019

Conditions

Myelodysplastic Syndromes

Outcome Measures

Primary Outcomes (1)

  • Survival of patients with myelodysplastic syndrome(MDS)

    Overall survival of all patients with MDS who are taken in charge in Institut Paoli Calmettes Cancer Center

    10 years

Secondary Outcomes (1)

  • Collection of patients characteristics

    10 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with new diagnosis of Myelodysplastic Syndromes

You may qualify if:

  • Patient with a diagnosis of Myelodysplastic Syndromes

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut Paoli-Calmettes

Marseille, PACA, 13009, France

RECRUITING

MeSH Terms

Conditions

Myelodysplastic Syndromes

Condition Hierarchy (Ancestors)

Bone Marrow DiseasesHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Norbert Vey, Pr

    Institut Paoli-Calmettes

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dominique Genre, MD

CONTACT

+33491223778drci.up@ipc.unicancer.fr

Lilian Laborde

CONTACT

+33491223778abordel@ipc.unicancer.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 6, 2017

First Posted

September 7, 2017

Study Start

January 18, 2016

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

December 1, 2030

Last Updated

May 14, 2019

Record last verified: 2019-05

Locations

FR(1)